sunitinib,pazopanib,pembrolizumab,tivozanib,cabozantinib,nivolumab,ipilimumab
merck,novartis,bms,pfizer,aveo oncology,ipsen
['pembro', 'sunitinib', 'pazopanib', 'rcc,(-irccs),(-srcc),(-urcc)', 'cabozantinib', ' ipi ', 'renal,(-adrenal)', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', 'tivozanib']
4. just prior to #gu23 we had a chance to discuss current soc of rcc w/ full interview: - - also on the oncology brothers podcast
- algorithm we used during our discussion attached below &amp; algo by 
Practice changing #Oncology news from #CommunityOncologists perspective w/ Rohit Gosain @UPMCHillmanCC & Rahul Gosain @WilmotCancer. Views are our own.